Current status of non-viral vectors for siRNA delivery.
- Author:
Fei-Fei YANG
1
;
Wei HUANG
;
Yun-Fei LI
;
Zhong-Gao GAO
Author Information
1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cell-Penetrating Peptides;
chemistry;
Chitosan;
chemistry;
Drug Carriers;
chemistry;
Genetic Vectors;
Half-Life;
Humans;
Imines;
chemistry;
Liposomes;
chemistry;
Neoplasms;
therapy;
Polyethylenes;
chemistry;
RNA Interference;
RNA, Small Interfering;
administration & dosage;
genetics;
therapeutic use;
Transfection
- From:
Acta Pharmaceutica Sinica
2011;46(12):1436-1443
- CountryChina
- Language:Chinese
-
Abstract:
RNA interference (RNAi) is a newly developed technology. It is the different levels of gene silencing induced by specific degradation of targeted genes in vivo, and both exogenous and endogenous double-stranded RNAs could induce the specific degradation. RNAi has been applied in tumor therapy, viral infection, hepatitis B and many other diseases. siRNA is the effector molecule which induces the RNAi in vivo. But naked siRNA is easily degradated by RNases in vivo, and the half-life is short. Meanwhile, the transfection efficiency of the naked siRNA is comparatively low. So the naked siRNA needs the help of vectors to penetrate the cell membrane and take action. Viral vectors have the potential immunogenicity and mutagenicity in gene therapy. Therefore, non-viral vectors are drawing more and more attention. The latest development of the non-viral vectors is summarized in this review.
